Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System : Case Study and Review of the Literature
© 2021 AlphaMed Press..
HER2 amplification, which results in overexpression of the receptor tyrosine kinase HER2, has been described in a wide variety of malignancies. HER2-targeting agents have been incorporated into the treatment paradigms for HER2-overexpressing breast and gastric cancer. More recently, these agents have shown promise in other gastrointestinal malignancies, such as colon cancer and biliary tract tumors. This study discusses two patients with gallbladder carcinoma and a third with ampullary carcinoma who were able to achieve marked responses to HER2-directed therapy. These cases underscore the importance of molecular analysis for HER2 amplification/HER2 overexpression, irrespective of tumor histology, and highlight a need for further investigation of HER2-directed therapy beyond breast and gastroesophageal cancers. KEY POINTS: Current guidelines recommend molecular assessment for HER2 overexpression exclusively in breast and gastric adenocarcinoma. The focus of this report is on three cases (two biliary tract and one ampullary carcinoma) in which amplification of HER2 or overexpression of HER2 was detected and treatment with HER2-directed therapy resulted in robust responses. These cases exemplify responsiveness of non-breast/gastric histologies to HER2-directed therapies, highlighting several promising new settings for these agents. Testing for amplification of HER2 or overexpression of HER2 should be considered especially in rare diseases with limited treatment options.
| Errataetall: |
CommentIn: Oncologist. 2021 Sep;26(9):e1664. - PMID 34156737 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
The oncologist - 26(2021), 8 vom: 25. Aug., Seite 640-646 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
May, Michael [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ampullary carcinoma |
|---|
| Anmerkungen: |
Date Completed 28.09.2021 Date Revised 29.10.2022 published: Print-Electronic CommentIn: Oncologist. 2021 Sep;26(9):e1664. - PMID 34156737 Citation Status MEDLINE |
|---|
| doi: |
10.1002/onco.13800 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324496567 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324496567 | ||
| 003 | DE-627 | ||
| 005 | 20231225190439.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/onco.13800 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1081.xml |
| 035 | |a (DE-627)NLM324496567 | ||
| 035 | |a (NLM)33896096 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a May, Michael |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System |b Case Study and Review of the Literature |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2021 | ||
| 500 | |a Date Revised 29.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Oncologist. 2021 Sep;26(9):e1664. - PMID 34156737 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 AlphaMed Press. | ||
| 520 | |a HER2 amplification, which results in overexpression of the receptor tyrosine kinase HER2, has been described in a wide variety of malignancies. HER2-targeting agents have been incorporated into the treatment paradigms for HER2-overexpressing breast and gastric cancer. More recently, these agents have shown promise in other gastrointestinal malignancies, such as colon cancer and biliary tract tumors. This study discusses two patients with gallbladder carcinoma and a third with ampullary carcinoma who were able to achieve marked responses to HER2-directed therapy. These cases underscore the importance of molecular analysis for HER2 amplification/HER2 overexpression, irrespective of tumor histology, and highlight a need for further investigation of HER2-directed therapy beyond breast and gastroesophageal cancers. KEY POINTS: Current guidelines recommend molecular assessment for HER2 overexpression exclusively in breast and gastric adenocarcinoma. The focus of this report is on three cases (two biliary tract and one ampullary carcinoma) in which amplification of HER2 or overexpression of HER2 was detected and treatment with HER2-directed therapy resulted in robust responses. These cases exemplify responsiveness of non-breast/gastric histologies to HER2-directed therapies, highlighting several promising new settings for these agents. Testing for amplification of HER2 or overexpression of HER2 should be considered especially in rare diseases with limited treatment options | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Ampullary carcinoma | |
| 650 | 4 | |a Biliary tract cancer | |
| 650 | 4 | |a Gallbladder carcinoma | |
| 650 | 4 | |a HER2 amplification | |
| 650 | 4 | |a Precision medicine | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Raufi, Alexander G |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghi, Sina |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Iuga, Alina |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Firas |e verfasserin |4 aut | |
| 700 | 1 | |a Bates, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Manji, Gulam A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The oncologist |d 1998 |g 26(2021), 8 vom: 25. Aug., Seite 640-646 |w (DE-627)NLM095483306 |x 1549-490X |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2021 |g number:8 |g day:25 |g month:08 |g pages:640-646 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/onco.13800 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2021 |e 8 |b 25 |c 08 |h 640-646 | ||